Development of Vaccine Strategies for the Treatment of B-Cell Malignancies

References

• Csatarty L K, Eckhardt S, Bukosza I, Czeldei F, Fenyvosi C, Gergily P, Bodey B. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prevent 1993; 17: 619
   PubMedGoogle Scholar
• Failkow P, Klein J E, Klein G, Clifford P, Singh S. Immunoglobulin and glucose 6 phosphate dehydrogenase as markers of cellular origin in Burkitt's lymphoma. J Exp Med 1973; 138: 89
   PubMed Web of Science ®Google Scholar
• Preud' Homme J L, Seligmann M. Surface bound immunoglobulin as a cell marker in human lymphoproliferative diseases. Blood 1972; 40: 777
   PubMed Web of Science ®Google Scholar
• Stevenson G T, Stevenson F K. Antibody to molecularly defined antigen confined to a tumor cell surface. Nature 1975; 254: 714
   PubMed Web of Science ®Google Scholar
• Sirisinha S, Eisen H N. Autoimmune-like antibodies to the ligand-binding sites of myeloma protein. Proc Natl Acad Sci USA 1971; 68: 3130
   PubMed Web of Science ®Google Scholar
• Jorgensen T, Gausemack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol 1980; 11: 29
   PubMed Web of Science ®Google Scholar
• Daley M J, Gebel H M, Lynch R G. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J Immunol 1978; 120: 1620
   PubMed Web of Science ®Google Scholar
• Bridges S H. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 1978; 121: 479
   PubMed Web of Science ®Google Scholar
• Freedman P M, Autry J R, Tokuda S, et al. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J Natl Cancer Inst 1976; 56: 735
   PubMed Web of Science ®Google Scholar
• Sugai S, Palmer D W, Talal N, et al. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW Fl mice. J Exp Med 1974; 140: 1547
   PubMedGoogle Scholar
• Stevenson F K, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol 1983; 130: 970
   PubMed Web of Science ®Google Scholar
• George A JT, Tutt A L, Stevenson F K. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987; 138: 628
   PubMed Web of Science ®Google Scholar
• Campbell M J, Esserman L, Byars N E, et al. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145: 1029
   PubMed Web of Science ®Google Scholar
• George A JT, Folkard S G, Hamblin T J, et al. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1990; 141: 2168
   Web of Science ®Google Scholar
• Campbell M J, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141: 3227
   PubMed Web of Science ®Google Scholar
• Meeker T C, Lowder J, Maloney D G, Miller R A, Thielemans K, Warnke R, Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349
   PubMed Web of Science ®Google Scholar
• Brown S L, Miller R A, Horning S J, Czerwinski D, Hart S M, McElderry R, Basham T, Warnke R A, Merigan T C, Levy R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651
   PubMed Web of Science ®Google Scholar
• Maloney D G, Brown S, Czerwinski D K, Liles T M, Hart S M, Miller R A, Levy R. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992; 80: 1502
   PubMed Web of Science ®Google Scholar
• Yancopoulos G D, Alt F W. Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol 1986; 4: 339
   PubMed Web of Science ®Google Scholar
• Alt F W, Baltimore D. Joining of immunoglobulin heavy chain gene segments: Implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci USA 1982; 79: 4118
   PubMed Web of Science ®Google Scholar
• Sanz I. Multiple mechanisms participate in the generation of diversity of human H chain CDR 3 regions. J Immunol 1991; 147: 1720
   PubMed Web of Science ®Google Scholar
• Wu T, Johnson G, Kabat E. Length distribution of CDRH3 in antibodies. Protein Struc Funct Genet 1993; 16: 1
   PubMed Web of Science ®Google Scholar
• Segal G H, Jorgenson T, Masih A S, Braylan R C. Optimal primer selection for clonality assessment by polymerase chain reaction analysis. I. Low grade B cell lymphoproliferative disorders of nonfollicular center cell type. Hum Pathol 1994; 25: 1264
   PubMedGoogle Scholar
• Kwak L W, Campbell M J, Czerwinski D, et al. Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209
   PubMed Web of Science ®Google Scholar
• Livingston P O. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147
   PubMed Web of Science ®Google Scholar
• Bogen B, Malissen B, Haas W. Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 1986; 16: 1373
   PubMed Web of Science ®Google Scholar
• Waters S J, Bona C A. Characterization of a T cell clone recognizing idiotypes as tumor-associated antigens. Cell Immunol 1988; 111: 87
   PubMed Web of Science ®Google Scholar
• Wright A, Lee J E, Link M P, et al. Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor and chain. J Exp Med 1989; 169: 1557
   PubMed Web of Science ®Google Scholar
• Wilson A, George A JT, King C A, et al. Recognition of a B cell lymphoma by anti-idiotypic T cells. J Immunol 1990; 145: 3937
   PubMed Web of Science ®Google Scholar
• Weiss S, Bogen B. MHC class-II restricted presentation of intracellular antigen. Cell 1991; 64: 767
   PubMed Web of Science ®Google Scholar
• Chakrabarti D, Ghosh S K. Induction of syngeneic T lymphocytes against a B cell tumor. Cell Immunol 1992; 144: 443
   PubMed Web of Science ®Google Scholar
• Cao W, Myers-Powell B A, Braciale T J. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 1994; 179: 195
   PubMed Web of Science ®Google Scholar
• Wigzell H. On the relationship between cellular and humoral antibodies. Contemp Top Imunobiol 1974; 3: 77
   PubMedGoogle Scholar
• Getzoff E D, Tainer J A, Lerner R A. The chemistry and mechanism of antibody binding to protein antigens. Adv Immunol 1988; 43: 1
   PubMed Web of Science ®Google Scholar
• Townsend A, Bodmer H. Antigen recognition by class I restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601
   PubMed Web of Science ®Google Scholar
• Babbitt B P, Allen P M, Matsueda G, Haber E, Unanue E R. Binding of immunogenic peptides to la histocompatibility molecules. Nature 1985; 317: 359
   PubMed Web of Science ®Google Scholar
• Goldberg A L, Rock K L. Proteolysis, proteasomes and antigen presentation. Nature 1992; 357: 375
   PubMed Web of Science ®Google Scholar
• Kensil C R, Patel U, Lennick M, et al. Separation and characterization of saponins with adjuvant activity from Qillaja saponaria molina cortex. J Immunol 1991; 146: 431
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow W JW, Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992; 89: 8308
   PubMed Web of Science ®Google Scholar
• Kawamura H, Rosenberg S A, Berzofsky T A. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med 1985; 162: 381
   PubMed Web of Science ®Google Scholar
• Hughes H PA, Campos M, Godson D L, et al. Immunopotentiation of bovine herpes virus subunit vaccination by inter-leukin-2. Immunology 1991; 164: 188
   Google Scholar
• Playfair J HL, Desouza J B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clin Exp Immunol 1987; 67: 5
   PubMed Web of Science ®Google Scholar
• Heath A W, Devey M E, Brown I N, et al. Interferon-gamma as an adjuvant in immunocompromised mice. Immunology 1989; 67: 520
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin 12, A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008
   PubMed Web of Science ®Google Scholar
• Afonso L CC, Scharton T M, Vieira L Q, Wysocka M, Tinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235
   Google Scholar
• Brynestad K, Babbitt B, Huang L, et al. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1–23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J Virol 1990; 64: 680
   PubMed Web of Science ®Google Scholar
• Reddy R, Zhou F, Nair S, et al. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 1992; 148: 1585
   PubMed Web of Science ®Google Scholar
• Harding C V, Collins D S, Kanagawa O, et al. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J Immunol 1991; 147: 2860
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Noguchi T, Sato T, et al. Priming for in vitro and in vivo anti-human T lymphotropic virus type 1 cellular immunity by virus-related protein reconstituted into liposome. J Immunol 1991; 146: 3599
   PubMed Web of Science ®Google Scholar
• White K, Krzych U, Gordon D M, et al. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine 1993; 11: 1341
   PubMed Web of Science ®Google Scholar
• Levitsky H I, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo D L, Kwak L W. Immunization with Gm-CSF-transduced, but not B7–1-transduced, lymphoma cells primes idiotype specific T cells and generates potent systemic anti-tumor immunity. J Immunol 1996; 156: 3858
   PubMed Web of Science ®Google Scholar
• Fynan E F, Webster R G, Fuller D H, Haynes J R, Santoro J C, Robinson H L. DNA vaccines: Protective immunizations by parenteral, mucosal and gene gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478
   PubMed Web of Science ®Google Scholar
• Watanabe A, Raz E, Kohsaka H, Tighe H, Baird S M, Kipps T J, Carson D A. Induction of antibodies to a K V region by gene immunization. J Immunol 1993; 151: 2871
   PubMed Web of Science ®Google Scholar
• Geissler E K, Wang J, Fechner J H, Burlingham W J, Knechtle S J. Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. J Immunol 1994; 152: 413
   PubMed Web of Science ®Google Scholar
• Ulmer J B, Donnelly J J, Parker S E, Rhodes G H, Feigner P L, Dwarki V J, Gromkowski S H, Deck R R, Dewitt C M, Friedman A, Hawe L A, Leander K R, Martinez D, Perry H C, Shiver J W, Montgomery D L, Liu M A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hedstrom R, Hobart P, Hoffman S L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci LISA 1994; 91: 9866
   PubMed Web of Science ®Google Scholar
• Hawkins R E, Winter G, Hambling T J, Stevenson F K, Russell S J. A genetic approach to idiotypic vaccination. J Immunother 1993; 14: 273
   Web of Science ®Google Scholar
• Stover C K, De La Cruz V F, Fuerst T R, et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456
   PubMed Web of Science ®Google Scholar
• Aldovini A, Young R A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991; 351: 479
   PubMed Web of Science ®Google Scholar
• Jacobs W R, Snapper S B, Lugosi L, et al. Development of BCG as a recombinant vaccine delivery vehicle. Curr Top Microbiol Immunol 1990; 155: 153
   PubMed Web of Science ®Google Scholar
• Cox W I, Tartaglia J, Paoletti E. Poxvirus Recombinants as Live Vaccines. CRC Press, Boca Raton, FL 1992
   Google Scholar
• Kwak L W, Taub D D, Duffey P L, Bensinger W I, Bryant E M, Reynolds C W, Longo D L. Transfer of myeloma idiotype-specific immunity from an actively immune marrow donor. Lancet 1995; 345: 1016
   PubMed Web of Science ®Google Scholar
• Kabat E A, Wu T T, Perry H M, Gottesman K S, Foeller C. Sequences of Proteins of Immunological Interest. Bethesda, MD 1991; 91–3242, NIH Publication no.
   Google Scholar
• Molecular Cloning: A Laboratory Manual, J Gambrook, E F Fritsch, T Maniatis. Cold Spring Harbor, Plainview, NY
   Google Scholar